ClinicalTrials.gg
CompletedNCT01744106Updated Apr 22, 2016

A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold

A Phase 3 interventional study of pseudoephedrine hydrochloride 30 mg tablets and Placebo tablets in Nasal Congestion Associated With the Common Cold, sponsored by Perrigo Company. Completed at 11 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2016-04-22.

Sponsored by Perrigo Company · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
565
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Common Cold with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Common Cold · United States.

Enrollment
8th of 40
565 · median 228
Started
2012
with 4 others
Phase 3
7 of 47
none open now
Registered
26th of 47
by date

Among the 47 studies in Common Cold with a site in United States, this one is the 8th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2012, is one of 7 in phase 3, and was the 26th registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

7 of the 47 studies in Common Cold with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Common Cold studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Common Cold with a site in United States, or all of them as a file.
02

Study summary

This study is designed to confirm the effectiveness of single-ingredient pseudoephedrine in children for the temporary relief of nasal congestion due to the common cold, an indication described under 21 CFR 341.80(b)(1).

03

Conditions studied

  • Nasal Congestion Associated With the Common Cold

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, ages 6 through 11 years, are experiencing the common cold, but are otherwise healthy.
  2. Subjects have an onset of cold symptoms within the past 2.5 days before screening and are experiencing self-reported nasal congestion of at least stuffy severity (score = 3 or 4).
  3. Subjects have at least two of the following additional symptoms due to common cold: runny nose, sneezing, sore throat, headache, body achiness, and cough, as deemed by the parent.
  4. Subjects can swallow oral tablets without chewing them (based on a pretest of successfully swallowing a placebo tablet at screening)
  5. Findings from the medical history review and vital signs are within the range of clinical acceptability, as determined by the investigator.
  6. Subject and legally authorized representative are likely to be compliant and complete the study.
  7. Subject's legally authorized representative has signed and dated the form. Subject has given verbal assent, and has signed and dated the informed assent form.
  8. Female subjects who have reached menarche must have a negative urine pregnancy test at screening. These subjects must have practiced abstinence for at least three months prior to study entry and for the duration of the study. A second pregnancy test will be given when the subject returns to the clinic after the last dose.
  9. Subject and legally authorized representative can read and understand English.
  10. Subject's legally authorized representative who signs informed consent is available to administer all assessments and study medication on days 1 and 2.

Exclusion criteria

Exclusion Criteria:

  1. Have any of the following medical conditions: heart disease, high blood pressure, thyroid disease, diabetes, peripheral vascular disease, increased intraocular pressure, prostatic hypertrophy
  2. Are under treatment for a hyperexcitability disorder with a medication regimen that has not been stable for at least 3 months
  3. Are currently experiencing an asthmatic episode
  4. Are experiencing symptoms of seasonal or perennial allergic rhinitis
  5. Are currently or within the last 24 hours having symptoms of vomiting or diarrhea
  6. Have been exposed to immediate family members with the flu within the past week
  7. Are exhibiting signs or symptoms of, or diagnosed with sinusitis, pneumonia, strep throat, acute otitis media, or influenza
  8. Are experiencing a fever 103˚F or higher at screening
  9. Are from homes where there is smoking in the home around the child.
  10. Are currently taking a monoamine oxidase inhibitor (MAOI), or have taken a MAOI within two weeks of screening (e.g., isocarboxazid - Marplan, phenelzine - Nardil, selegiline - Eldepryl, Emsam, Zelapar, and tranylcypromine - Parnate). Note: subjects may not discontinue taking a MAOI solely of the purposes of qualifying for the study.
  11. Have a known sensitivity or allergy to pseudoephedrine, phenylephrine, or acetaminophen or any of the of the drug product
  12. Have taken any oral cold or allergy medicine within 12 hours of enrollment, or intranasal decongestants within 24 hours of enrollment except for single-ingredient OTC analgesics
  13. Have the need to take additional medications, including cough and cold (i.e., oral or intranasal antihistamines, intranasal , intranasal decongestants), or herbal/dietary supplements during the study, with the exception of acetaminophen, a medication regimen for a hyperexcitability disorder that has been stable for at least three months or a daily vitamin or multivitamin/multimineral supplement
  14. Have participated in another clinical study within 30 days before entry
  15. Have another child from the household currently participating in this study
  16. Have a history of drug, alcohol, or tobacco use (older children)
  17. Are involved directly or indirectly with the conduct and administration of this study (i.e., children of principal investigator, subinvestigator, study coordinators, other study personnel, employees of Perrigo, and the families of each).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
565 participants (actual)

Study arms

  • Experimental
    pseudoephedrine hydrochloride 30 mg tablets

    Test product

    Drug: pseudoephedrine hydrochloride 30 mg tablets

  • Placebo comparator
    placebo tablets

    Placebo

    Drug: Placebo tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Nasal Congestion Severity (NCSi) (instantaneous) scores

    Weighted sum of change from baseline in Nasal Congestion Severity (NCSi) (instantaneous) scores over the first eight hours of treatment on Day 1

    Time frame: 1 Day

Secondary outcomes

  1. change from baseline in NCSi scores from 0 to 4 hours

    Sum of change from baseline in NCSi scores from 0 to 4 hours after the first dose on Day 1

    Time frame: Day 1

  2. change from baseline in NCSi scores from 6, 7, and 8 hours

    Weighted sum of change from baseline in NCSi scores from 6, 7, and 8 hours after the first dose on Day 1

    Time frame: Day 1

  3. Nasal Congestion Relief (NCR) reflective scores at 4 hours and 8 hours

    Sum of Nasal Congestion Relief (NCR) reflective scores at 4 hours and 8 hours on Day 1

    Time frame: Day 1

  4. NCSi score at each time point from 0 to 8 hours

    NCSi score at each time point from 0 to 8 hours after the first dose on Day 1

    Time frame: Day 1

  5. NCSr (reflective) scores at 6 hours and 12 hours

    Sum of NCSr (reflective) scores at 6 hours and 12 hours on Day 2

    Time frame: Day 2

  6. NCSr scores at 6 and 12 hours

    NCSr scores at 6 and 12 hours on Day 2

    Time frame: Day 2

Other outcomes

  1. change from baseline in the Nasal Symptom and Function (NSF) composite score of NCSi

    Weighted sum of change from baseline in the Nasal Symptom and Function (NSF) composite score of NCSi, nasal breathing, and nasal clearing over the first eight hours of treatment on Day 1

    Time frame: Day 1

  2. Sum of change from baseline in NSF composite score from 0 to 4 hours

    Sum of change from baseline in NSF composite score from 0 to 4 hours after the first dose on Day 1

    Time frame: Day 1

  3. Weighted sum of change from baseline in NSF composite score from 6, 7, and 8 hours

    Weighted sum of change from baseline in NSF composite score from 6, 7, and 8 hours after the first dose on Day 1

    Time frame: Day 1

  4. morning sleep score on Days 2 through 7

    Change from baseline in morning sleep score on Days 2 through 7

    Time frame: Day 7

  5. NSF composite score on Days 2 through 7

    Change from baseline in NSF composite score on Days 2 through 7

    Time frame: Day 7

  6. NSF + S (sleep) composite score on Days 2 through 7

    Change from baseline in the NSF + S (sleep) composite score on Days 2 through 7

    Time frame: Day 7

07

Study locations

11 sites
  • Emmaus Research Center
    Anaheim, California 92804, United States
  • WCCT Global, LLC
    Costa Mesa, California 92626, United States
  • Advanced Clinical Research - Boise
    Boise, Idaho 83642, United States
  • Bluegrass Clinical Research
    Louisville, Kentucky 40291, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134, United States
  • Rapid Medical Research
    Cleveland, Ohio 44122, United States
  • Carolina Ear, Nose and Throat Clinic
    Orangeburg, South Carolina 29118, United States
  • Meridian Clinical Research - Dakota Dunes
    Dakota Dunes, South Dakota 57049, United States
  • ClinPoint Trials, LLC
    Waxahachie, Texas 75165, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • Advanced Clinical Research - West Jordan
    West Jordan, Utah 84088, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2012
First posted
Dec 6, 2012
Start
Nov 2012
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
Apr 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01744106
Lead sponsor
Perrigo Company
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Nov 2012
Primary completion
Apr 2016
Completion
Apr 2016
Last update
Apr 22, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pseudoephedrine

Start the discussion